Cargando…
Identification of Immune Activation Markers in the Early Onset of COVID-19 Infection
This study aimed to determine the specific cytokine profile in peripheral blood during the early onset of COVID-19 infection. This was a cross-sectional exploratory, single center study. A total of 55 plasma samples were studied. Serum samples of adults showing symptoms of COVID-19 infection who wer...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446609/ https://www.ncbi.nlm.nih.gov/pubmed/34540715 http://dx.doi.org/10.3389/fcimb.2021.651484 |
_version_ | 1784568916858634240 |
---|---|
author | Kovarik, Johannes J. Kämpf, Anna K. Gasser, Fabian Herdina, Anna N. Breuer, Monika Kaltenecker, Christopher C. Wahrmann, Markus Haindl, Susanne Mayer, Florian Traby, Ludwig Touzeau-Roemer, Veronique Grabmeier-Pfistershammer, Katharina Kussmann, Manuel Robak, Oliver Willschke, Harald Ay, Care Säemann, Marcus D. Schmetterer, Klaus G. Strassl, Robert |
author_facet | Kovarik, Johannes J. Kämpf, Anna K. Gasser, Fabian Herdina, Anna N. Breuer, Monika Kaltenecker, Christopher C. Wahrmann, Markus Haindl, Susanne Mayer, Florian Traby, Ludwig Touzeau-Roemer, Veronique Grabmeier-Pfistershammer, Katharina Kussmann, Manuel Robak, Oliver Willschke, Harald Ay, Care Säemann, Marcus D. Schmetterer, Klaus G. Strassl, Robert |
author_sort | Kovarik, Johannes J. |
collection | PubMed |
description | This study aimed to determine the specific cytokine profile in peripheral blood during the early onset of COVID-19 infection. This was a cross-sectional exploratory, single center study. A total of 55 plasma samples were studied. Serum samples of adults showing symptoms of COVID-19 infection who were tested positive for SARS-CoV-2 infection (CoV+, n=18) at the COVID-19 outpatient clinic of the Medical University of Vienna were screened for immune activation markers by Luminex technology. Additionally, age and gender-matched serum samples of patients displaying COVID-19 associated symptoms, but tested negative for SARS-CoV-2 (CoV-, n=16) as well as healthy controls (HC, n=21) were analyzed. COVID-19 positive (CoV+) patients showed a specific upregulation of BLC (141; 74-189 pg/mL), SCD30 (273; 207-576 pg/mL), MCP-2 (18; 12-30 pg/mL) and IP-10 (37; 23-96 pg/mL), compared to patients with COVID19-like symptoms but negative PCR test (CoV-), BLC (61; 22-100 pg/mL), sCD30L (161; 120-210 pg/mL), MCP-2 (8; 5-12 pg/mL) and IP-10 (9; 6-12 pg/mL) and healthy controls (HC) (BLC 22; 11-36 pg/mL, sCD30 74; 39-108 pg/mL, MCP-2 6; 3-9. pg/mL, IP-10 = 8; 5-13). The markers APRIL, sIL-2R, IL7, MIF, MIP-1b, SCF, SDF-1a, sTNF-RII were elevated in both CoV+ and CoV- patient groups compared to healthy controls. HGF, MDC and VEGF-A were elevated in CoV- but not CoV+ compared to healthy controls. BLC, sCD30, MCP-2 and IP-10 are specifically induced during early stages of COVID-19 infection and might constitute attractive targets for early diagnosis and treatment of this disease. |
format | Online Article Text |
id | pubmed-8446609 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84466092021-09-18 Identification of Immune Activation Markers in the Early Onset of COVID-19 Infection Kovarik, Johannes J. Kämpf, Anna K. Gasser, Fabian Herdina, Anna N. Breuer, Monika Kaltenecker, Christopher C. Wahrmann, Markus Haindl, Susanne Mayer, Florian Traby, Ludwig Touzeau-Roemer, Veronique Grabmeier-Pfistershammer, Katharina Kussmann, Manuel Robak, Oliver Willschke, Harald Ay, Care Säemann, Marcus D. Schmetterer, Klaus G. Strassl, Robert Front Cell Infect Microbiol Cellular and Infection Microbiology This study aimed to determine the specific cytokine profile in peripheral blood during the early onset of COVID-19 infection. This was a cross-sectional exploratory, single center study. A total of 55 plasma samples were studied. Serum samples of adults showing symptoms of COVID-19 infection who were tested positive for SARS-CoV-2 infection (CoV+, n=18) at the COVID-19 outpatient clinic of the Medical University of Vienna were screened for immune activation markers by Luminex technology. Additionally, age and gender-matched serum samples of patients displaying COVID-19 associated symptoms, but tested negative for SARS-CoV-2 (CoV-, n=16) as well as healthy controls (HC, n=21) were analyzed. COVID-19 positive (CoV+) patients showed a specific upregulation of BLC (141; 74-189 pg/mL), SCD30 (273; 207-576 pg/mL), MCP-2 (18; 12-30 pg/mL) and IP-10 (37; 23-96 pg/mL), compared to patients with COVID19-like symptoms but negative PCR test (CoV-), BLC (61; 22-100 pg/mL), sCD30L (161; 120-210 pg/mL), MCP-2 (8; 5-12 pg/mL) and IP-10 (9; 6-12 pg/mL) and healthy controls (HC) (BLC 22; 11-36 pg/mL, sCD30 74; 39-108 pg/mL, MCP-2 6; 3-9. pg/mL, IP-10 = 8; 5-13). The markers APRIL, sIL-2R, IL7, MIF, MIP-1b, SCF, SDF-1a, sTNF-RII were elevated in both CoV+ and CoV- patient groups compared to healthy controls. HGF, MDC and VEGF-A were elevated in CoV- but not CoV+ compared to healthy controls. BLC, sCD30, MCP-2 and IP-10 are specifically induced during early stages of COVID-19 infection and might constitute attractive targets for early diagnosis and treatment of this disease. Frontiers Media S.A. 2021-09-03 /pmc/articles/PMC8446609/ /pubmed/34540715 http://dx.doi.org/10.3389/fcimb.2021.651484 Text en Copyright © 2021 Kovarik, Kämpf, Gasser, Herdina, Breuer, Kaltenecker, Wahrmann, Haindl, Mayer, Traby, Touzeau-Roemer, Grabmeier-Pfistershammer, Kussmann, Robak, Willschke, Ay, Säemann, Schmetterer and Strassl https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Kovarik, Johannes J. Kämpf, Anna K. Gasser, Fabian Herdina, Anna N. Breuer, Monika Kaltenecker, Christopher C. Wahrmann, Markus Haindl, Susanne Mayer, Florian Traby, Ludwig Touzeau-Roemer, Veronique Grabmeier-Pfistershammer, Katharina Kussmann, Manuel Robak, Oliver Willschke, Harald Ay, Care Säemann, Marcus D. Schmetterer, Klaus G. Strassl, Robert Identification of Immune Activation Markers in the Early Onset of COVID-19 Infection |
title | Identification of Immune Activation Markers in the Early Onset of COVID-19 Infection |
title_full | Identification of Immune Activation Markers in the Early Onset of COVID-19 Infection |
title_fullStr | Identification of Immune Activation Markers in the Early Onset of COVID-19 Infection |
title_full_unstemmed | Identification of Immune Activation Markers in the Early Onset of COVID-19 Infection |
title_short | Identification of Immune Activation Markers in the Early Onset of COVID-19 Infection |
title_sort | identification of immune activation markers in the early onset of covid-19 infection |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446609/ https://www.ncbi.nlm.nih.gov/pubmed/34540715 http://dx.doi.org/10.3389/fcimb.2021.651484 |
work_keys_str_mv | AT kovarikjohannesj identificationofimmuneactivationmarkersintheearlyonsetofcovid19infection AT kampfannak identificationofimmuneactivationmarkersintheearlyonsetofcovid19infection AT gasserfabian identificationofimmuneactivationmarkersintheearlyonsetofcovid19infection AT herdinaannan identificationofimmuneactivationmarkersintheearlyonsetofcovid19infection AT breuermonika identificationofimmuneactivationmarkersintheearlyonsetofcovid19infection AT kalteneckerchristopherc identificationofimmuneactivationmarkersintheearlyonsetofcovid19infection AT wahrmannmarkus identificationofimmuneactivationmarkersintheearlyonsetofcovid19infection AT haindlsusanne identificationofimmuneactivationmarkersintheearlyonsetofcovid19infection AT mayerflorian identificationofimmuneactivationmarkersintheearlyonsetofcovid19infection AT trabyludwig identificationofimmuneactivationmarkersintheearlyonsetofcovid19infection AT touzeauroemerveronique identificationofimmuneactivationmarkersintheearlyonsetofcovid19infection AT grabmeierpfistershammerkatharina identificationofimmuneactivationmarkersintheearlyonsetofcovid19infection AT kussmannmanuel identificationofimmuneactivationmarkersintheearlyonsetofcovid19infection AT robakoliver identificationofimmuneactivationmarkersintheearlyonsetofcovid19infection AT willschkeharald identificationofimmuneactivationmarkersintheearlyonsetofcovid19infection AT aycare identificationofimmuneactivationmarkersintheearlyonsetofcovid19infection AT saemannmarcusd identificationofimmuneactivationmarkersintheearlyonsetofcovid19infection AT schmettererklausg identificationofimmuneactivationmarkersintheearlyonsetofcovid19infection AT strasslrobert identificationofimmuneactivationmarkersintheearlyonsetofcovid19infection |